Aurinia Pharmaceuticals Inc. — Form 8-K
Filed August 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Aurinia and subsidiary settled patent infringement litigation with Teva Pharmaceuticals over Teva's generic voclosporin 7.9 mg capsules. Under the settlement, Teva stipulated that Aurinia's U.S. Patents 10,286,036 and 11,622,991 (expiring December 2037) are valid and would be infringed; Teva may not launch generics before December 7, 2036, unless contingencies occur earlier. Aurinia continues patent litigation against seven other generic manufacturers (DifGen, Dr. Reddy's, Hikma, Lotus, Sandoz, Zydus, and affiliates) in the U.S. District Court for the District of New Jersey.
Why this rating
Settlement extends monopoly protection on LUPKYNIS (voclosporin)—Aurinia's primary commercial product—by ~10.5 years, securing substantial revenue. Relative to $1B market cap, market exclusion through 2036 is material and trajectory-positive, though contingent on other generics remaining blocked.
See more from August 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.